Fiche société
Vertex Pharmaceuticals Incorporated
Traitements, essais et publications liés.
Traitements5programmes
Essais3liés
Publications0liées
SourceDBlocale
Traitements
5| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| PovetaciceptThe purpose of this study is to evaluate the pharmacodynamic (PD) effect, safety, and tolerability of Povetacicept in participants with generalized myasthenia gravis (gMG). | Myasthénie | Phase 2 | À vérifier | United States, Australia, Poland, Turkey (Türkiye), United Kingdom | À vérifier |
| VX-670The purpose of the study is to evaluate the long-term safety and tolerability, efficacy and pharmacokinetics of VX-670 in participants with Myotonic Dystrophy Type I (DM1). | Myopathies | Phase 1/2 | À vérifier | United States, Australia, Belgium, Canada, France, Germany, Italy, Netherlands, … | À vérifier |
| VX-670The purpose of the study is to evaluate the long-term safety and tolerability, efficacy and pharmacokinetics of VX-670 in participants with Myotonic Dystrophy Type I (DM1). | Myopathies | Phase 2 | À vérifier | United States, Australia, Belgium, Canada, Germany, Netherlands, Spain, United Kingdom | À vérifier |
| PovetaciceptThe purpose of this study is to evaluate the pharmacodynamic (PD) effect, safety, and tolerability of Povetacicept in participants with generalized myasthenia gravis (gMG). | Myasthénie | Phase 2 | À vérifier | United States, Australia, Poland, Turkey (Türkiye), United Kingdom | À vérifier |
| VX-670The purpose of the study is to evaluate the long-term safety and tolerability, efficacy and pharmacokinetics of VX-670 in participants with Myotonic Dystrophy Type I (DM1). | Myopathies | Phase 1/2 | À vérifier | United States, Australia, Belgium, Canada, France, Germany, Italy, Netherlands, Spain, United Kingdom | À vérifier |
Essais cliniques
3| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| VX-670 | Myopathies | Phase 1/2 | NCT06185764 | Galileo — A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | ACTIVE_NOT_RECRUITING |
| Povetacicept | Myasthénie | Phase 2 | NCT07501702 | ETNA — A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis | RECRUITING |
| VX-670 | Myopathies | Phase 2 | NCT06926621 | A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I | ENROLLING_BY_INVITATION |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||